Literature DB >> 19060426

Differences in serum phospholipid fatty acid compositions and estimated desaturase activities between Japanese men with and without metabolic syndrome.

Chizuko Maruyama1, Megumi Yoneyama, Noriko Suyama, Kasuya Yoshimi, Ai Teramoto, Yuka Sakaki, Yasuyo Suto, Kei Takahashi, Risa Araki, Yuko Ishizaka, Minoru Yamakado, Tamio Teramoto.   

Abstract

AIM: This study was designed to clarify differences in serum phospholipid fatty acid compositions and estimated desaturase activities between Japanese men with and without metabolic syndrome (MetS).
METHODS: From among 227 males, 40 to 59 years of age, excluding those receiving treatment for lipid disorders, 165 subjects (including 27 with MetS) were selected for this study. Serum phospholipid fatty acid compositions were determined, and desaturase activities were estimated.
RESULTS: The C15:0 and C17:0 fatty acids associated with hepatic function were lower, while the C20:3n-6 and C20:4n-3 fatty acids were higher, in subjects with than without MetS (p<0.05). The estimated desaturase activity for D5D(n-6) was lower in subjects with than without MetS (p<0.01). Body fat percentage was an independent negative predictor of C17:0, and a positive predictor of log C20:3n-6 and log C20:4n-3 (p<0.01). HDL-C was an independent negative predictor of log C15:0 and of C17:0 (p<0.01).
CONCLUSION: Decreases in minor saturated fatty acids, accumulation of C20:3n-6 and C20:4n-3 and low estimated D5D activity were confirmed to be associated with MetS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19060426     DOI: 10.5551/jat.e564

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  7 in total

1.  Low blood levels of long-chain n-3 polyunsaturated fatty acids in US hemodialysis patients: clinical implications.

Authors:  Allon N Friedman; Zhangsheng Yu; Rebeka Tabbey; Cheryl Denski; Hector Tamez; Julia Wenger; Ravi Thadhani; Yong Li; Bruce A Watkins
Journal:  Am J Nephrol       Date:  2012-11-02       Impact factor: 3.754

2.  Disclosing ambiguous gene aliases by automatic literature profiling.

Authors:  Roney S Coimbra; Dana E Vanderwall; Guilherme C Oliveira
Journal:  BMC Genomics       Date:  2010-12-22       Impact factor: 3.969

3.  Increased Dietary Intake of Saturated Fatty Acid Heptadecanoic Acid (C17:0) Associated with Decreasing Ferritin and Alleviated Metabolic Syndrome in Dolphins.

Authors:  Stephanie K Venn-Watson; Celeste Parry; Mark Baird; Sacha Stevenson; Kevin Carlin; Risa Daniels; Cynthia R Smith; Richard Jones; Randall S Wells; Sam Ridgway; Eric D Jensen
Journal:  PLoS One       Date:  2015-07-22       Impact factor: 3.240

4.  Efficacy of dietary odd-chain saturated fatty acid pentadecanoic acid parallels broad associated health benefits in humans: could it be essential?

Authors:  Stephanie Venn-Watson; Richard Lumpkin; Edward A Dennis
Journal:  Sci Rep       Date:  2020-05-18       Impact factor: 4.379

5.  Modified fish diet shifted serum metabolome and alleviated chronic anemia in bottlenose dolphins (Tursiops truncatus): Potential role of odd-chain saturated fatty acids.

Authors:  Stephanie Venn-Watson; Mark Baird; Brittany Novick; Celeste Parry; Eric D Jensen
Journal:  PLoS One       Date:  2020-04-07       Impact factor: 3.240

6.  Plasma phospholipid fatty acid composition and estimated desaturase activity in heart failure patients with metabolic syndrome.

Authors:  Seungmin Lee; Hyun Ju Do; Seok-Min Kang; Ji Hyung Chung; Eunju Park; Min-Jeong Shin
Journal:  J Clin Biochem Nutr       Date:  2012-07-06       Impact factor: 3.114

7.  Relationship between acute phase proteins and serum fatty acid composition in morbidly obese patients.

Authors:  Ricardo Fernandes; Bruna Teles Soares Beserra; Raphael Salles Granato Cunha; Elaine Hillesheim; Carolina de Quadros Camargo; Danielle Cristina Tonello Pequito; Isabela Coelho de Castro; Luiz Cláudio Fernandes; Everson Araújo Nunes; Erasmo Benício Santos de Moraes Trindade
Journal:  Dis Markers       Date:  2013-07-28       Impact factor: 3.434

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.